ABBV-400 + bevacizumab

ABBV-400 + bevacizumab is an investigational combination therapy for metastatic colorectal cancer (mCRC) and other advanced solid tumors. **ABBV-400** (also known as telisotuzumab adizutecan) is an antibody-drug conjugate (ADC) targeting c-Met, a receptor tyrosine kinase commonly overexpressed in these cancers, comprised of the monoclonal antibody telisotuzumab linked to a novel topoisomerase 1 inhibitor payload. **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), blocking angiogenesis. This combination is being studied for its potential enhanced anti-tumor efficacy through dual inhibition of tumor growth (c-Met pathway) and tumor angiogenesis (VEGF pathway), particularly in mCRC patients who have progressed after previous therapies[1][2][3][5].